<DOC>
	<DOCNO>NCT00446056</DOCNO>
	<brief_summary>The clinical study evaluate safety montelukast compare montelukast ketotifen , use control drug , term improvement morning peak expiratory flow ( pef ) first 2 week patient pediatric bronchial asthma age 6 &lt; 15 . The effect body weight efficacy safety montelukast also evaluate study .</brief_summary>
	<brief_title>Montelukast Post-Marketing Comparative Study With Ketotifen ( 0476-379 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<criteria>Intermittent asthma , mild persistent asthma , moderate persistent asthma , severe persistent asthma patient 2 mild moderate attack baseline Patient use antiasthma treatment therapy include corticosteroid oral antiallergic drug Patient complication impair judgment efficacy drug Patient convulsive disorder epilepsy history Patient liver disease , renal impairment , heart disease complication</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>